• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

冠心病患者对衣原体抗原的淋巴细胞反应。

Lymphocyte responses to Chlamydia antigens in patients with coronary heart disease.

作者信息

Halme S, Syrjälä H, Bloigu A, Saikku P, Leinonen M, Airaksinen J, Surcel H M

机构信息

National Public Health Institute, Oulu, Finland.

出版信息

Eur Heart J. 1997 Jul;18(7):1095-101. doi: 10.1093/oxfordjournals.eurheartj.a015403.

DOI:10.1093/oxfordjournals.eurheartj.a015403
PMID:9243142
Abstract

AIMS

To clarify the relationship of Chlamydia pneumoniae infection and coronary atherosclerosis we studied cell-mediated and humoral immune responses to Chlamydia in 93 patients with angiographically confirmed coronary heart disease and in 115 controls without angiographically demonstrable lesions.

METHODS AND RESULTS

Cell-mediated responses were analysed by measuring lymphocyte proliferative reactivity to whole elementary body antigens of C. pneumoniae. Control antigens included C. trachomatis and purified protein derivative of tuberculin. Chlamydia-specific antibodies were measured using microimmunofluorescence assay. Marked C. pneumoniae-specific immune reactivity, demonstrated by the high incidence of elevated IgG and IgA antibodies and strong lymphocyte proliferative response, was associated with coronary heart disease in male but not in female patients or controls. In male patients, the cell-mediated responses were strong to C. pneumoniae (median stimulation index 9,6) and to C. trachomatis (stimulation index 6,9). The females with coronary heart disease showed significantly stronger cell-mediated responses to C. pneumoniae (stimulation index 6,5) than to C. trachomatis (3,8; P < 0.001) and were comparable to the controls.

CONCLUSION

Marked cell-mediated and humoral immunity to C. pneumoniae in males with coronary heart disease suggest that the immune mechanisms triggered by Chlamydia are a possible contributing factor in the disease pathogenesis of coronary atherosclerosis in males. The Chlamydia-specific cell-mediated responses seem to be predominantly induced by antigenic structures that are similar among different Chlamydia-species.

摘要

目的

为阐明肺炎衣原体感染与冠状动脉粥样硬化之间的关系,我们研究了93例经血管造影证实患有冠心病的患者以及115例无血管造影可见病变的对照者对衣原体的细胞介导免疫和体液免疫反应。

方法与结果

通过检测淋巴细胞对肺炎衣原体全原体抗原的增殖反应性来分析细胞介导反应。对照抗原包括沙眼衣原体和结核菌素纯蛋白衍生物。使用微量免疫荧光测定法检测衣原体特异性抗体。IgG和IgA抗体升高的高发生率以及强烈的淋巴细胞增殖反应所显示的明显的肺炎衣原体特异性免疫反应性,与男性冠心病患者相关,而与女性患者或对照者无关。在男性患者中,细胞介导反应对肺炎衣原体(中位刺激指数9.6)和沙眼衣原体(刺激指数6.9)均较强。患有冠心病的女性对肺炎衣原体的细胞介导反应(刺激指数6.5)明显强于对沙眼衣原体的反应(3.8;P<0.001),且与对照者相当。

结论

男性冠心病患者对肺炎衣原体有明显的细胞介导免疫和体液免疫,这表明衣原体触发的免疫机制可能是男性冠状动脉粥样硬化疾病发病机制中的一个促成因素。衣原体特异性细胞介导反应似乎主要由不同衣原体物种间相似的抗原结构诱导产生。

相似文献

1
Lymphocyte responses to Chlamydia antigens in patients with coronary heart disease.冠心病患者对衣原体抗原的淋巴细胞反应。
Eur Heart J. 1997 Jul;18(7):1095-101. doi: 10.1093/oxfordjournals.eurheartj.a015403.
2
Chlamydia pneumoniae-specific cell-mediated and humoral immunity in healthy people.健康人群中肺炎衣原体特异性细胞免疫和体液免疫
Scand J Immunol. 1998 May;47(5):517-20. doi: 10.1046/j.1365-3083.1998.00332.x.
3
Chlamydia pneumoniae: risk factors for seropositivity and association with coronary heart disease.肺炎衣原体:血清阳性的危险因素及其与冠心病的关联
J Infect. 1995 Mar;30(2):121-8. doi: 10.1016/s0163-4453(95)80006-9.
4
Antibodies to 60-kilodalton heat shock protein and outer membrane protein 2 of Chlamydia pneumoniae in patients with coronary heart disease.冠心病患者中针对肺炎衣原体60千道尔顿热休克蛋白和外膜蛋白2的抗体。
Clin Diagn Lab Immunol. 2002 Jan;9(1):66-74. doi: 10.1128/cdli.9.1.66-74.2002.
5
Chlamydia pneumoniae antibodies and angiographically demonstrated coronary artery disease in Thailand.泰国肺炎衣原体抗体与血管造影显示的冠状动脉疾病
J Med Assoc Thai. 2000 Sep;83(9):1054-8.
6
Immunocomb Chlamydia bivalent assay to study Chlamydia species-specific antibodies in patients with coronary heart disease.免疫组合衣原体二价检测法用于研究冠心病患者中衣原体属特异性抗体。
Indian J Med Res. 2005 Mar;121(3):171-5.
7
Relationship between Chlamydia pneumoniae infection, inflammatory markers, and coronary heart diseases.肺炎衣原体感染、炎症标志物与冠心病之间的关系。
Int Immunopharmacol. 2006 May;6(5):848-53. doi: 10.1016/j.intimp.2005.10.012. Epub 2005 Nov 28.
8
[Chlamydia antibody titers in patients with coronary disease: relations to age and clinical stage].[冠心病患者的衣原体抗体滴度:与年龄及临床分期的关系]
Wien Klin Wochenschr. 2001 Oct 15;113(19):727-30.
9
Diagnosis of Chlamydia pneumoniae infection in patients with chronic obstructive pulmonary disease by micro-immunofluorescence and ELISA.采用微量免疫荧光法和酶联免疫吸附测定法诊断慢性阻塞性肺疾病患者的肺炎衣原体感染
J Med Microbiol. 1997 Nov;46(11):959-64. doi: 10.1099/00222615-46-11-959.
10
Serum reactivity to Chlamydia trachomatis and C. pneumoniae antigens in patients with documented infection and in healthy children by microimmunofluorescence and immunoblotting techniques.采用微量免疫荧光和免疫印迹技术检测有确诊感染的患者及健康儿童血清对沙眼衣原体和肺炎衣原体抗原的反应性。
APMIS. 1993 Sep;101(9):719-26.

引用本文的文献

1
Anti-inflammatory therapy in atherosclerotic cardiovascular disease: Current reappraisal.动脉粥样硬化性心血管疾病中的抗炎治疗:当前重新评估
Indian Heart J. 2023 Nov-Dec;75(6):391-397. doi: 10.1016/j.ihj.2023.10.007. Epub 2023 Oct 26.
2
Advances in immune-modulating therapies to treat atherosclerotic cardiovascular diseases.用于治疗动脉粥样硬化性心血管疾病的免疫调节疗法的进展。
Ther Adv Vaccines. 2014 Mar;2(2):56-66. doi: 10.1177/2051013613514327.
3
Atherosclerosis: humoral and cellular factors of inflammation.动脉粥样硬化:炎症的体液和细胞因素
Virchows Arch. 2005 Feb;446(2):101-11. doi: 10.1007/s00428-004-1180-4. Epub 2005 Feb 2.
4
Cell-mediated immune response during primary Chlamydia pneumoniae infection.肺炎衣原体初次感染期间的细胞介导免疫反应。
Infect Immun. 2000 Dec;68(12):7156-8. doi: 10.1128/IAI.68.12.7156-7158.2000.
5
Microorganisms in the aetiology of atherosclerosis.动脉粥样硬化病因中的微生物。
J Clin Pathol. 2000 Sep;53(9):647-54. doi: 10.1136/jcp.53.9.647.
6
Chlamydia pneumoniae and atherosclerosis.肺炎衣原体与动脉粥样硬化
Heart. 1999 Mar;81(3):232-8. doi: 10.1136/hrt.81.3.232.